JZYY(SH:600750) Zhong Guo Zheng Quan Bao·2026-01-23 13:33Core Viewpoint - Jiangzhong Pharmaceutical (600750) reported a revenue of 4.22 billion yuan for 2025, a year-on-year decrease of 4.87%, while the net profit attributable to shareholders increased by 14.96% to 906 million yuan [4] Financial Performance - The company achieved a net profit of 906 million yuan, representing a 14.96% increase year-on-year [4] - The non-recurring net profit was 832 million yuan, with a year-on-year growth of 11.1% [4] - Basic earnings per share stood at 1.43 yuan, and the weighted average return on equity was 22.74%, an increase of 3.16 percentage points from the previous year [15] Valuation Metrics - As of January 23, the price-to-earnings ratio (TTM) was approximately 16.43 times, the price-to-book ratio (LF) was about 3.91 times, and the price-to-sales ratio (TTM) was around 3.39 times [4] - The historical price-to-earnings ratio trend indicates fluctuations in the company's valuation over recent years [5][6] Business Strategy - The company is focused on strengthening its core business through brand development, optimizing marketing strategies, and enhancing cost efficiency to improve profitability [11]